REGENERON PHARMACEUTICALS, INC. — Director's Dealing 2021

Dec 6, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: REGENERON PHARMACEUTICALS, INC. (REGN)
CIK: 0000872589
Period of Report: 2021-12-03

Reporting Person: STAHL NEIL (EVP Research and Development)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-11-29	Common Stock	G	4605	$0.0	Disposed	28809	Direct
2021-12-03	Common Stock	M	72500	$179.13	Acquired	101309	Direct
2021-12-03	Common Stock	F	50352	$632.45	Disposed	50957	Direct
2021-11-29	Common Stock	G	4605	$0.0	Acquired	4605	Indirect

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-12-03	Non-Qualified Stock Option (right to buy)	$179.13	M	72500	Disposed	2022-12-14	Common Stock (72500)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	5792	Indirect

Footnotes

F1: The stock option award vests in four equal annual installments, commencing one year after the date of grant.